IRadimed Corporation(IRMD)Earnings, Financials & Key Ratios

IRMD•NASDAQ

$86.24

$1.1B mkt cap·49.3× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryPatient monitoring and wearable diagnostics

AboutIRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Show more

Revenue$84M+14.4%
EBITDA$29M+25.2%
Net Income$22M+16.9%
EPS (Diluted)1.75+16.7%
Gross Margin76.75%-0.2%
EBITDA Margin34.04%+9.4%
Operating Margin31.2%+4.0%
Net Margin26.82%+2.1%
ROE24.78%+1.9%
ROIC50.16%-11.0%

Technical→

IRMD Key Insights

IRadimed Corporation (IRMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 24.3%
✓Strong 5Y profit CAGR of 75.0%
✓FCF machine: 20.5% free cash flow margin
✓Strong 5Y sales CAGR of 21.5%
✓Healthy 5Y average net margin of 25.1%

✗Weaknesses

✗Expensive at 11.7x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

IRMD Price & Volume

IRadimed Corporation (IRMD) stock price & volume — 10-year historical chart

Loading chart...

IRMD Growth Metrics

IRadimed Corporation (IRMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years10.25%

5 Years21.45%

3 Years16.28%

TTM14.81%

Profit CAGR

10 Years11.56%

5 Years75.02%

3 Years20.56%

TTM19.34%

EPS CAGR

10 Years11.3%

5 Years73.91%

3 Years19.71%

TTM18.06%

Return on Capital

10 Years18.22%

5 Years22.95%

3 Years26.83%

Last Year27.76%

IRMD Recent Earnings

IRadimed Corporation (IRMD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 9/12 qtrs (75%)

Q2 2026Latest

May 1, 2026

EPS

$0.49

Est $0.46

+6.5%

Revenue

$22M

Est $21M

+3.1%

Q1 2026

Feb 10, 2026

EPS

$0.54

Est $0.49

+10.2%

Revenue

$23M

Est $22M

+5.1%

Q4 2025

Nov 3, 2025

EPS

$0.47

Est $0.48

-2.1%

Revenue

$21M

Est $22M

-1.8%

Q3 2025

Aug 1, 2025

EPS

$0.49

Est $0.45

+8.9%

Revenue

$20M

Est $20M

-0.4%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 1, 2026	$0.49vs $0.46+6.5%	$22Mvs $21M+3.1%
Q1 2026	Feb 10, 2026	$0.54vs $0.49+10.2%	$23Mvs $22M+5.1%
Q4 2025	Nov 3, 2025	$0.47vs $0.48-2.1%	$21Mvs $22M-1.8%
Q3 2025	Aug 1, 2025	$0.49vs $0.45+8.9%	$20Mvs $20M-0.4%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
LNTHLantheus Holdings, Inc.Direct Competitor	5.61B	86.15	25.26	0.5%	15.15%	20.58%	0.00
PRCTPROCEPT BioRobotics CorporationDirect Competitor	1.41B	24.80	-14.42	37.22%	-31.82%	-27.7%	0.14
ANGOAngioDynamics, Inc.Direct Competitor	459.4M	11.05	-13.31	-3.76%	-9.02%	-15.71%
NVCRNovoCure LimitedDirect Competitor	1.88B	16.50	-13.52	8.28%	-25.66%	-50.82%	0.85
GEHCGE HealthCare Technologies Inc.Product Competitor	28.08B	61.74	13.57	4.84%	7.54%	14.45%	0.94
STESTERIS plcProduct Competitor	21.09B	214.52	34.60	6.24%	12.14%	9.87%	0.33
MMSIMerit Medical Systems, Inc.Product Competitor	3.68B	61.63	28.93	11.66%	9.03%	8.95%	0.57
INVAInnoviva, Inc.Product Competitor	1.91B	22.52	6.82	18.52%	118.91%	46.47%	0.23

Compare IRMD vs Peers

IRadimed Corporation (IRMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LNTH

Most directly comparable listed peer for IRMD.

Scale Benchmark

vs ISRG

Larger-name benchmark to compare IRMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs LNTH, PRCT, ANGO, NVCR

IRMD Income Statement

IRadimed Corporation (IRMD) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	23.08M	30.44M	38.52M	31.72M	41.81M	53.3M	65.56M	73.24M	83.81M	86.28M
Revenue Growth %	-28.97%	31.88%	26.54%	-17.65%	31.83%	27.47%	23%	11.71%	14.43%	14.81%
Cost of Goods Sold	5.57M	7.21M	8.82M	8.14M	9.76M	12.02M	15.4M	16.89M	19.49M	19.99M
COGS % of Revenue	24.13%	23.69%	22.89%	25.67%	23.35%	22.55%	23.5%	23.06%	23.25%	-
Gross Profit	17.51M▲ 0%	23.23M▲ 32.6%	29.7M▲ 27.9%	23.57M▼ 20.6%	32.05M▲ 36.0%	41.28M▲ 28.8%	50.16M▲ 21.5%	56.35M▲ 12.3%	64.32M▲ 14.2%	66.3M▲ 0%
Gross Margin %	75.87%	76.31%	77.11%	74.33%	76.65%	77.45%	76.5%	76.94%	76.75%	76.84%
Gross Profit Growth %	-33.52%	32.64%	27.87%	-20.63%	35.95%	28.81%	21.5%	12.34%	14.15%	-
Operating Expenses	16.23M	17.22M	21.05M	24.33M	22.23M	25.65M	30.12M	34.39M	38.18M	38.34M
OpEx % of Revenue	70.3%	56.58%	54.66%	76.71%	53.17%	48.13%	45.95%	46.95%	45.55%	-
Selling, General & Admin	14.5M	15.71M	19.62M	22.43M	20.33M	23.38M	27.26M	31.55M	35.2M	35.04M
SG&A % of Revenue	62.84%	51.6%	50.94%	70.71%	48.61%	43.86%	41.59%	43.08%	42%	-
Research & Development	1.72M	1.52M	1.43M	1.9M	1.91M	2.28M	2.86M	2.83M	2.98M	3.31M
R&D % of Revenue	7.46%	4.98%	3.72%	6%	4.56%	4.27%	4.36%	3.87%	3.55%	-
Other Operating Expenses	111.38K	0	0	0	0	0	0	0	0	0
Operating Income	1.29M▲ 0%	6M▲ 367.2%	8.65M▲ 44.0%	-756.09K▼ 108.7%	9.82M▲ 1398.5%	15.63M▲ 59.2%	20.04M▲ 28.2%	21.96M▲ 9.6%	26.15M▲ 19.0%	27.95M▲ 0%
Operating Margin %	5.57%	19.72%	22.45%	-2.38%	23.48%	29.32%	30.56%	29.99%	31.2%	32.4%
Operating Income Growth %	-88.23%	367.22%	44.03%	-108.74%	1398.48%	59.18%	28.21%	9.63%	19.04%	-
EBITDA	1.73M	6.56M	9.89M	582.73K	11.22M	16.3M	20.8M	22.78M	28.53M	29.54M
EBITDA Margin %	7.5%	21.56%	25.68%	1.84%	26.84%	30.58%	31.73%	31.11%	34.04%	34.24%
EBITDA Growth %	-84.51%	279.33%	50.68%	-94.11%	1826.18%	45.2%	27.62%	9.53%	25.22%	26.07%
D&A (Non-Cash Add-back)	445.27K	559.73K	1.24M	1.34M	1.41M	670.67K	765.18K	817.66K	2.38M	1.59M
EBIT	1.4M	6.2M	8.65M	-756.09K	9.82M	15.63M	20.04M	21.96M	26.15M	28.96M
Net Interest Income	122.58K	238.11K	388.8K	132.19K	34.81K	581.85K	1.86M	2.19M	0	0
Interest Income	122.58K	238.11K	388.8K	132.19K	34.81K	581.85K	1.86M	2.19M	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	111.38K	193.54K	395.91K	139.21K	18.61K	553.1K	1.7M	2.31M	2.21M	2.23M
Pretax Income	1.4M▲ 0%	6.2M▲ 343.8%	9.04M▲ 45.9%	-616.88K▼ 106.8%	9.84M▲ 1694.5%	16.18M▲ 64.5%	21.74M▲ 34.3%	24.28M▲ 11.7%	28.36M▲ 16.8%	30.18M▲ 0%
Pretax Margin %	6.05%	20.36%	23.48%	-1.94%	23.52%	30.36%	33.16%	33.14%	33.84%	34.98%
Income Tax	896.62K	-106.14K	-587.64K	-1.99M	510.82K	3.35M	4.55M	5.04M	5.88M	6.57M
Effective Tax Rate %	64.21%	-1.71%	-6.5%	321.92%	5.19%	20.72%	20.91%	20.77%	20.74%	21.78%
Net Income	499.76K▲ 0%	6.3M▲ 1161.3%	9.63M▲ 52.8%	1.37M▼ 85.8%	9.33M▲ 581.2%	12.83M▲ 37.6%	17.19M▲ 34.0%	19.23M▲ 11.9%	22.48M▲ 16.9%	23.61M▲ 0%
Net Margin %	2.17%	20.71%	25%	4.32%	22.3%	24.07%	26.22%	26.26%	26.82%	27.36%
Net Income Growth %	-93.07%	1161.29%	52.79%	-85.79%	581.19%	37.56%	34.02%	11.87%	16.88%	19.34%
Net Income (Continuing)	499.76K	6.3M	9.63M	1.37M	9.33M	12.83M	17.19M	19.23M	22.48M	23.61M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	0.04▲ 0%	0.52▲ 1200.0%	0.78▲ 50.0%	0.11▼ 85.9%	0.74▲ 572.7%	1.02▲ 37.8%	1.35▲ 32.4%	1.50▲ 11.1%	1.75▲ 16.7%	1.83▲ 0%
EPS Growth %	-93.33%	1200%	50%	-85.9%	572.73%	37.84%	32.35%	11.11%	16.67%	18.06%
EPS (Basic)	0.05	0.52	0.85	0.11	0.76	1.02	1.36	1.52	1.77	-
Diluted Shares Outstanding	11.72M	12.11M	12.28M	12.44M	12.59M	12.64M	12.72M	12.78M	12.85M	12.87M
Basic Shares Outstanding	10.64M	12.11M	11.28M	12.12M	12.35M	12.56M	12.6M	12.67M	12.72M	12.78M
Dividend Payout Ratio	-	-	-	-	-	97.9%	76.91%	71.11%	66.9%	-

IRMD Balance Sheet

IRadimed Corporation (IRMD) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	35.11M	44.54M	58.96M	63.74M	76.24M	77.49M	76M	75.24M	81.2M	86.42M
Cash & Short-Term Investments	26.34M	34.38M	46.25M	51.98M	62.5M	57.96M	49.76M	52.23M	51.16M	56.37M
Cash Only	18.21M	28.03M	43.48M	50.07M	62M	57.96M	49.76M	52.23M	51.16M	56.37M
Short-Term Investments	8.14M	6.35M	2.77M	1.91M	501.86K	0	0	0	0	0
Accounts Receivable	3.78M	4.21M	7.29M	4.57M	5.14M	13.27M	12.22M	10.56M	13.67M	0
Days Sales Outstanding	59.76	50.48	69.11	52.65	44.84	90.9	68.06	52.61	59.52	40.66
Inventory	4.21M	4.06M	3.64M	3.93M	4.3M	5.37M	12.82M	10.4M	11.62M	0
Days Inventory Outstanding	275.94	205.46	150.77	176.34	160.73	163.03	303.8	224.76	217.61	157.76
Other Current Assets	648.88K	526.79K	407.8K	771.67K	1M	630.96K	1.19M	2.05M	4.76M	30.05M
Total Non-Current Assets	3.9M	3.9M	7.77M	7.33M	6.64M	8.02M	16.15M	23.08M	27.57M	27.97M
Property, Plant & Equipment	1.87M	1.87M	5.01M	4.84M	4.55M	4.61M	11.33M	16.97M	23.86M	24.23M
Fixed Asset Turnover	12.35x	16.28x	7.69x	6.56x	9.19x	11.57x	5.79x	4.32x	3.51x	3.64x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	885.5K	832.52K	860.09K	960.88K	1.12M	2.07M	2.52M	3.1M	3.38M	3.29M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	200.2K	109.76K	232K	261.99K	201.32K	648.67K	181.45K	198.91K	239K	1.11M
Total Assets	39.01M▲ 0%	48.44M▲ 24.2%	66.73M▲ 37.7%	71.07M▲ 6.5%	82.88M▲ 16.6%	85.51M▲ 3.2%	92.16M▲ 7.8%	98.33M▲ 6.7%	108.78M▲ 10.6%	114.39M▲ 0%
Asset Turnover	0.59x	0.63x	0.58x	0.45x	0.50x	0.62x	0.71x	0.74x	0.77x	0.78x
Asset Growth %	4.89%	24.17%	37.75%	6.5%	16.63%	3.18%	7.77%	6.69%	10.63%	63.14%
Total Current Liabilities	4.08M	4.69M	5.86M	4.92M	6.82M	8.55M	16.33M	8.51M	10.18M	12.12M
Accounts Payable	656.72K	772.47K	993.74K	657.05K	782.9K	1.8M	1.86M	1.9M	1.82M	2.18M
Days Payables Outstanding	43.04	39.1	41.14	29.45	29.26	54.63	44	40.98	34.08	37.6
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1.62M	1.8M	1.67M	1.95M	2.55M	3.37M	2.57M	2.26M	2.87M	12.68M
Other Current Liabilities	278.61K	315.94K	190.18K	236.49K	255.31K	94.03K	367.46K	268.27K	457K	6.54M
Current Ratio	8.61x	9.50x	10.06x	12.96x	11.18x	9.06x	4.65x	8.84x	7.98x	7.98x
Quick Ratio	7.58x	8.63x	9.44x	12.16x	10.54x	8.43x	3.87x	7.62x	6.84x	6.84x
Cash Conversion Cycle	292.66	216.85	178.74	199.53	176.3	199.3	327.85	236.39	243.05	160.82
Total Non-Current Liabilities	2M	1.81M	5.35M	4.76M	3.88M	3.29M	4.41M	2.99M	3.98M	3.76M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	2.72M	2.46M	2.21M	1.91M	1.62M	1.42K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	3.76M
Total Liabilities	6.08M	6.5M	11.2M	9.68M	10.71M	11.84M	20.74M	11.51M	14.16M	15.88M
Total Debt	0	0	2.96M	2.72M	2.48M	2.21M	2.04M	154.69K	0	0
Net Debt	-18.21M	-28.03M	-40.53M	-47.35M	-59.52M	-55.76M	-47.72M	-52.08M	-51.16M	-56.37M
Debt / Equity	-	-	0.05x	0.04x	0.03x	0.03x	0.03x	0.00x	-	0.00x
Debt / EBITDA	-	-	0.30x	4.66x	0.22x	0.14x	0.10x	0.01x	-	0.00x
Net Debt / EBITDA	-10.52x	-4.27x	-4.10x	-81.26x	-5.30x	-3.42x	-2.29x	-2.29x	-1.79x	-1.79x
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity	32.93M▲ 0%	41.95M▲ 27.4%	55.52M▲ 32.4%	61.38M▲ 10.6%	72.17M▲ 17.6%	73.67M▲ 2.1%	71.42M▼ 3.1%	86.82M▲ 21.6%	94.62M▲ 9.0%	98.51M▲ 0%
Equity Growth %	3.27%	27.38%	32.37%	10.55%	17.58%	2.08%	-3.06%	21.56%	8.98%	54.62%
Book Value per Share	2.81	3.46	4.52	4.93	5.73	5.83	5.61	6.79	7.36	7.65
Total Shareholders' Equity	32.93M	41.95M	55.52M	61.38M	72.17M	73.67M	71.42M	86.82M	94.62M	98.51M
Common Stock	1.06K	1.1K	1.18K	1.23K	1.25K	1.26K	1.26K	1.27K	1K	1K
Retained Earnings	20.36M	26.67M	36.3M	37.67M	46.99M	47.26M	43.26M	56.79M	64.23M	67.49M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-48.91K	-42.19K	30.37K	37.09K	17.01K	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

IRMD Cash Flow Statement

IRadimed Corporation (IRMD) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	3.42M	7.38M	10.23M	5.82M	11.26M	10.04M	13.47M	25.62M	24.95M	24.95M
Operating CF Margin %	14.8%	24.23%	26.57%	18.34%	26.92%	18.84%	20.54%	34.99%	29.76%	-
Operating CF Growth %	-63.68%	115.93%	38.73%	-43.15%	93.52%	-10.8%	34.08%	90.3%	-2.64%	85.39%
Net Income	499.76K	6.3M	9.63M	1.37M	9.33M	12.83M	17.19M	19.23M	22.48M	23.61M
Depreciation & Amortization	1.31M	1.11M	1.24M	1.34M	1.41M	670.67K	765.18K	817.66K	1.17M	1.43M
Stock-Based Compensation	2.45M	1.76M	1.85M	3.96M	1.46M	1.39M	2.19M	2.52M	2.92M	2.11M
Deferred Taxes	-150.66K	-144.43K	-596.75K	389.93K	523.61K	57.1K	-1.17M	-697.65K	0	401.94K
Other Non-Cash Items	424.97K	155.66K	68.69K	-70.07K	119.04K	148.74K	402.32K	-3.02K	2.73M	4.25M
Working Capital Changes	-1.12M	-1.81M	-1.97M	-1.17M	-1.58M	-5.06M	-5.91M	3.75M	-4.34M	-2.85M
Change in Receivables	-201.59K	-446.9K	-3.11M	2.69M	-575.54K	-8.24M	841.91K	1.76M	-3.03M	-680.45K
Change in Inventory	-334.11K	-121.59K	123.68K	-282.9K	-393.32K	-1.31M	-7.47M	3.13M	-1.38M	-1.79M
Change in Payables	-523.45K	34.16K	149.32K	-403.57K	30.41K	1.12M	-216.44K	-861.62K	-76K	-407.64K
Cash from Investing	-1.02M	1.52M	3.2M	246.97K	648.24K	-1.37M	-8.01M	-8.82M	-8.42M	-4.97M
Capital Expenditures	-824.76K	-264.67K	-368.28K	-636.75K	-482.32K	-823.02K	-7.44M	-8.01M	-7.76M	-4.6M
CapEx % of Revenue	3.57%	0.87%	0.96%	2.01%	1.15%	1.54%	11.35%	10.93%	9.26%	-
Acquisitions	49.19K	36.35K	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-49.19K	-36.35K	-117.53K	0	-259.43K	-1.05M	-566.66K	-811.75K	-656K	-376.23K
Cash from Financing	-1.9M	929.87K	2.02M	522.48K	24.43K	-12.71M	-13.66M	-14.34M	-17.6M	-17.93M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	-1.82M	0	0	1.73M	0	0	0	29.62K	0	0
Dividends Paid	0	0	0	0	0	-12.56M	-13.22M	-13.68M	-15.04M	-15.43M
Share Repurchases	-1.82M	-309.56K	0	0	0	0	0	0	0	0
Other Financing	-81.77K	929.87K	2.02M	-1.21M	24.43K	-147.27K	-433.6K	-688.16K	-2.56M	-2.49M
Net Change in Cash	492.11K▲ 0%	9.82M▲ 1895.9%	15.45M▲ 57.3%	6.59M▼ 57.4%	11.93M▲ 81.1%	-4.04M▼ 133.9%	-8.2M▼ 103.0%	2.47M▲ 130.1%	-1.07M▼ 143.5%	6.04M▲ 0%
Free Cash Flow	2.59M▲ 0%	7.11M▲ 174.4%	9.75M▲ 37.1%	5.18M▼ 46.8%	10.52M▲ 103.0%	8.17M▼ 22.3%	5.46M▼ 33.2%	17.62M▲ 222.8%	17.18M▼ 2.5%	24.1M▲ 0%
FCF Margin %	11.23%	23.36%	25.31%	16.33%	25.15%	15.32%	8.32%	24.06%	20.5%	27.93%
FCF Growth %	-67.13%	174.45%	37.06%	-46.85%	102.99%	-22.33%	-33.18%	222.83%	-2.48%	72.16%
FCF per Share	0.22	0.59	0.79	0.42	0.84	0.65	0.43	1.38	1.34	1.34
FCF Conversion (FCF/Net Income)	6.84x	1.17x	1.06x	4.25x	1.21x	0.78x	0.78x	1.33x	1.11x	1.02x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	1.21M	1.38M	12K	0	970K	1.71M	5.35M	6.51M	0	2.49M

IRMD Key Ratios

IRadimed Corporation (IRMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	1.54%	16.84%	19.76%	2.34%	13.96%	17.59%	23.7%	24.31%	24.78%	24.48%
Return on Invested Capital (ROIC)	6.67%	31.44%	44.86%	-3.91%	55.18%	76.67%	72.21%	56.38%	50.16%	50.16%
Gross Margin	75.87%	76.31%	77.11%	74.33%	76.65%	77.45%	76.5%	76.94%	76.75%	76.84%
Net Margin	2.17%	20.71%	25%	4.32%	22.3%	24.07%	26.22%	26.26%	26.82%	27.36%
Debt / Equity	-	-	0.05x	0.04x	0.03x	0.03x	0.03x	0.00x	-	0.00x
FCF Conversion	6.84x	1.17x	1.06x	4.25x	1.21x	0.78x	0.78x	1.33x	1.11x	1.02x
Revenue Growth	-28.97%	31.88%	26.54%	-17.65%	31.83%	27.47%	23%	11.71%	14.43%	14.81%

IRMD SEC Filings & Documents

IRadimed Corporation (IRMD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 1, 2026·SEC

Material company update

Feb 10, 2026·SEC

Material company update

Dec 8, 2025·SEC

10-K Annual Reports

FY 2026

Mar 6, 2026·SEC

FY 2025

Mar 6, 2025·SEC

FY 2024

Mar 1, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 1, 2026·SEC

FY 2025

Nov 3, 2025·SEC

FY 2025

Aug 1, 2025·SEC

IRMD Frequently Asked Questions

IRadimed Corporation (IRMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

IRadimed Corporation (IRMD) reported $86.3M in revenue for fiscal year 2025. This represents a 1023% increase from $7.7M in 2012.

IRadimed Corporation (IRMD) grew revenue by 14.4% over the past year. This is steady growth.

Yes, IRadimed Corporation (IRMD) is profitable, generating $23.6M in net income for fiscal year 2025 (26.8% net margin).

Dividend & Returns

Yes, IRadimed Corporation (IRMD) pays a dividend with a yield of 1.36%. This makes it attractive for income-focused investors.

IRadimed Corporation (IRMD) has a return on equity (ROE) of 24.8%. This is excellent, indicating efficient use of shareholder capital.

IRadimed Corporation (IRMD) generated $24.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More IRMD

IRadimed Corporation (IRMD) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

IRadimed Corporation(IRMD)Earnings, Financials & Key Ratios

IRMD Key Insights

✓Strengths

✗Weaknesses

IRMD Price & Volume

IRMD Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

IRMD Recent Earnings

IRMD Peer Comparison

Compare IRMD vs Peers

vs LNTH

vs ISRG

Compare Top 5

IRMD Income Statement

IRMD Balance Sheet

IRMD Cash Flow Statement

IRMD Key Ratios

IRMD SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

IRMD Frequently Asked Questions

Explore More IRMD

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation